Evidence map›Paper›PMID 31170814›Full record

ArticleFuture oncology (London, England)2019

Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients.

Joel M Michalski, Elizabeth R Lyden, Andrea J Lee, Zaid S Al-Kadhimi, Lori J Maness, Krishna Gundabolu, Vijaya Raj Bhatt

Open access · greenAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Joel M MichalskiDepartment of Internal Medicine, Section of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Elizabeth R LydenDepartment of Internal Medicine, Section of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Andrea J LeeDepartment of Internal Medicine, Section of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Zaid S Al-KadhimiDepartment of Internal Medicine, Section of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Lori J ManessDepartment of Internal Medicine, Section of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Krishna GundaboluDepartment of Internal Medicine, Section of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Vijaya Raj BhattDepartment of Internal Medicine, Section of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
University of Nebraska Medical Center · US

Funding

Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI RIZZO, MATTHEW · 2016 to 2025
$42.8M
NIGMS NIH HHS U54 GM115458
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntimetabolites, AntineoplasticDecitabineDose-Response Relationship, DrugFemaleHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMiddle AgedRemission InductionRetrospective StudiesTreatment OutcomeAntimetabolites, AntineoplasticDecitabine10-day decitabineacute myeloid leukemiafrail patientshypomethylating agentsolder adultsoverall survival

Identifiers

PMID31170814
PMCPMC6714071
OpenAlexW2953689191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.